Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - ALLIED HEALTHCARE PRODUCTS INC | Financial_Report.xls |
| EX-31.2 - EXHIBIT 31.2 - ALLIED HEALTHCARE PRODUCTS INC | v238658_ex31-2.htm |
| EX-32.1 - EXHIBIT 32.1 - ALLIED HEALTHCARE PRODUCTS INC | v238658_ex32-1.htm |
| EX-31.1 - EXHIBIT 31.1 - ALLIED HEALTHCARE PRODUCTS INC | v238658_ex31-1.htm |
| EX-32.2 - EXHIBIT 32.2 - ALLIED HEALTHCARE PRODUCTS INC | v238658_ex32-2.htm |
| 10-Q - 10-Q - ALLIED HEALTHCARE PRODUCTS INC | v238658_10q.htm |
Exhibit 99.1
|
Contact:
|
Daniel C. Dunn
|
Chief Financial Officer
314/771-2400
Allied Healthcare Products Reports
First Quarter Loss On Sales Decline
ST. LOUIS, November 8, 2011 – Allied Healthcare Products, Inc. (NASDAQ: AHPI) reported a loss in its first quarter on a decline in sales.
Allied’s net loss for the first quarter of its 2012 fiscal year was approximately $145,000, or a negative 2 cents per basic and diluted share, versus a loss of about $88,000, or a negative 1 cent per share, in the previous year’s first quarter.
Allied’s sales for the quarter ending September 30, 2011 totaled about $11.4 million. This represents a decline of approximately 4 percent from the previous year’s first quarter sales of about $11.9 million. Sales remain constrained by recession driven budget cuts in both hospitals and municipalities but the decline in sales between the two periods is believed by the Company to be a result of order timing rather than any further market declines.
The Company incurred expenses of about $400,000 in bringing production of Carbolime in-house during the first quarter. This production expense will be reduced by more than half in the second quarter and eliminated in the fiscal year’s third and fourth quarters, resulting in improved margins.
Allied also reported significantly higher commodity prices in the quarter. Prices for commodities such as brass and resin increased by more than 20 percent over prior year levels. Prices for non-commodity goods increased by about 4 percent over the prior year.
Allied Healthcare Products manufactures a variety of respiratory products used in the healthcare industry in a range of hospital and alternate care settings including sub-acute facilities, home healthcare and emergency medical care. Allied’s product lines include respiratory care products, medical gas equipment and emergency medical products. Allied’s products are marketed to hospitals, hospital equipment dealers, hospital construction contractors, home healthcare dealers and emergency medical products dealers.
“SAFE HARBOR” STATEMENT: Statements contained in this release that are not historical facts or information are “forward-looking statements.” Words such as “believe,” “expect,” “intend,” “will,” “should,” and other expressions that indicate future events and trends identify such forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome and future results of operations and financial condition to be materially different than stated or anticipated based on the forward-looking statements. Such risks and uncertainties include both general economic risks and uncertainties, risks and uncertainties affecting the demand for and economic factors affecting the delivery of health care services, and specific matters which relate directly to the Company’s operations and properties as discussed in its periodic filings with the Securities and Exchange Commission. The Company cautions that any forward-looking statement contained in this report reflects only the belief of the Company or its management at the time the statement was made. Although the Company believes such forward-looking statements are based upon reasonable assumptions, such assumptions may ultimately prove inaccurate or incomplete. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement was made.
##
ALLIED HEALTHCARE PRODUCTS, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
(UNAUDITED)
|
Three months ended September 30,
|
||||||||
|
2011
|
2010
|
|||||||
|
Net sales
|
$ | 11,395,008 | $ | 11,940,733 | ||||
|
Cost of sales
|
8,988,991 | 9,390,006 | ||||||
|
Gross profit
|
2,406,017 | 2,550,727 | ||||||
|
Selling, general and administrative expenses
|
2,634,089 | 2,684,576 | ||||||
|
Loss from operations
|
(228,072 | ) | (133,849 | ) | ||||
|
Other (income) expenses:
|
||||||||
|
Interest income
|
(8,994 | ) | (7,475 | ) | ||||
|
Interest expense
|
336 | 66 | ||||||
|
Other expense, net
|
14,405 | 15,100 | ||||||
| 5,747 | 7,691 | |||||||
|
Loss before benefit from income taxes
|
(233,819 | ) | (141,540 | ) | ||||
|
Benefit from income taxes
|
(88,851 | ) | (53,785 | ) | ||||
|
Net loss
|
$ | (144,968 | ) | $ | (87,755 | ) | ||
|
Basic and diluted loss per share
|
$ | (0.02 | ) | $ | (0.01 | ) | ||
|
Weighted average common shares outstanding - basic and diluted
|
8,124,386 | 8,093,386 | ||||||
ALLIED HEALTHCARE PRODUCTS, INC.
CONSOLIDATED BALANCE SHEET
(UNAUDITED)
|
September 30, 2011
|
June 30, 2011
|
|||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$ | 6,164,178 | $ | 6,512,887 | ||||
|
Accounts receivable, net of allowances of $300,000
|
5,146,927 | 5,366,860 | ||||||
|
Inventories, net
|
10,752,057 | 10,553,289 | ||||||
|
Income tax receivable
|
187,728 | 95,578 | ||||||
|
Other current assets
|
456,015 | 213,745 | ||||||
|
Total current assets
|
22,706,905 | 22,742,359 | ||||||
|
Property, plant and equipment, net
|
8,855,578 | 8,660,507 | ||||||
|
Other assets, net
|
359,420 | 362,480 | ||||||
|
Total assets
|
$ | 31,921,903 | $ | 31,765,346 | ||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$ | 1,796,735 | $ | 1,644,910 | ||||
|
Other accrued liabilities
|
1,961,130 | 1,645,552 | ||||||
|
Deferred income taxes
|
508,457 | 512,572 | ||||||
|
Deferred revenue
|
630,850 | 688,200 | ||||||
|
Total current liabilities
|
4,897,172 | 4,491,234 | ||||||
|
Deferred revenue
|
- | 114,700 | ||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders' equity:
|
||||||||
|
Preferred stock; $0.01 par value; 1,500,000 shares authorized; no shares issued and outstanding
|
- | - | ||||||
|
Series A preferred stock; $0.01 par value; 200,000 shares authorized; no shares issued and outstanding
|
- | - | ||||||
|
Common stock; $0.01 par value; 30,000,000 shares authorized; 10,427,878 shares issued at September 30, 2011 and June 30, 2011; 8,124,386 shares outstanding at September 30, 2011 and June 30, 2011
|
104,279 | 104,279 | ||||||
|
Additional paid-in capital
|
48,509,390 | 48,499,103 | ||||||
|
Accumulated deficit
|
(857,510 | ) | (712,542 | ) | ||||
|
Less treasury stock, at cost; 2,303,492 shares at
|
||||||||
|
September 30, 2011 and June 30, 2011
|
(20,731,428 | ) | (20,731,428 | ) | ||||
|
Total stockholders' equity
|
27,024,731 | 27,159,412 | ||||||
|
Total liabilities and stockholders' equity
|
$ | 31,921,903 | $ | 31,765,346 | ||||